BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 6134445)

  • 1. Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia.
    Shoulson I
    Adv Neurol; 1983; 37():259-66. PubMed ID: 6134445
    [No Abstract]   [Full Text] [Related]  

  • 2. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
    Bitton V; Melamed E
    J Clin Psychiatry; 1984 Jan; 45(1):28-30. PubMed ID: 6141157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Portable device for quantifying parkinsonian wrist rigidity.
    Caligiuri MP
    Mov Disord; 1994 Jan; 9(1):57-63. PubMed ID: 7908119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 5. Controlled-release carbidopa-levodopa: old drug--new drug. Introduction.
    Koller WC
    Neurology; 1992 Jan; 42(1 Suppl 1):4-5; discussion 57-60. PubMed ID: 1549200
    [No Abstract]   [Full Text] [Related]  

  • 6. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
    Fahn S
    Adv Neurol; 1983; 37():267-76. PubMed ID: 6858776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease.
    Barboi AC; Goetz CG
    Clin Neuropharmacol; 1999; 22(4):184-91. PubMed ID: 10442246
    [No Abstract]   [Full Text] [Related]  

  • 9. Coexistent tardive dyskinesia and parkinsonism.
    Jankovic J; Casabona J
    Clin Neuropharmacol; 1987 Dec; 10(6):511-21. PubMed ID: 2892586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 11. Parkinson's disease.
    Lieberman AN
    Compr Ther; 1986 Mar; 12(3):25-9. PubMed ID: 3486090
    [No Abstract]   [Full Text] [Related]  

  • 12. Parkinson's disease improvement after the addition of levodopa-carbidopa to anticholinergic treatment. An open controlled study.
    Agnoli A; Ruggieri S; Denaro A; Lelli A
    Acta Neurol (Napoli); 1978 Oct; 33(5):436-42. PubMed ID: 756675
    [No Abstract]   [Full Text] [Related]  

  • 13. [Combined therapy of carbidopa and levodopa in Parkinson's disease].
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):201-4. PubMed ID: 4075908
    [No Abstract]   [Full Text] [Related]  

  • 14. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

  • 15. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
    Savery F
    Curr Ther Res Clin Exp; 1976 Mar; 19(3):337-8. PubMed ID: 817863
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effects and side effects to levodopa in parkinsonism- results of a collaborative study. (5) Combined therapy with a peripheral decarboxylase inhibitor].
    Omoto T
    Rinsho Shinkeigaku; 1976 Dec; 16(12):879-80. PubMed ID: 1035531
    [No Abstract]   [Full Text] [Related]  

  • 17. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sinemet in Parkinson's disease: efficacy with and without food.
    Bozek CB; Suchowersky O; Purves S; Calne S; Calne DB
    Clin Neuropharmacol; 1986; 9(2):196-9. PubMed ID: 3708604
    [No Abstract]   [Full Text] [Related]  

  • 19. Clozapine withdrawal symptoms in a Parkinson's disease patient.
    Zesiewicz TA; Borra S; Hauser RA
    Mov Disord; 2002 Nov; 17(6):1365-7. PubMed ID: 12465085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-cell sensitivity modification (RSM) as a model for pathogenesis and treatment of tardive dyskinesia.
    Friedhoff AJ; Rosengarten H; Bonnet K
    Psychopharmacol Bull; 1978 Oct; 14(4):77-9. PubMed ID: 704769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.